Translational Radiation Oncologyy Research topic(s)

Translational Radiation Oncologyy
Research topic(s):
1. Identification of tumor-specific factors of resistance
2. Combination of radiotherapy with novel drugs for radiosensitisation
3. Individualisation of treatment by prediction of tumor response to radiotherapy
Group Leader
Prof. Dr. med. Mechthild Krause
Translational Radiation Oncology
Partner site Dresden of the German Cancer Consortium (DKTK)
And German Cancer Research Center (DKFZ) Heidelberg
Department of Radiotherapy and Radiation Oncology
Faculty of Medicine Carl Gustav Carus
Technische Universität Dresden (TUD)
Fetscherstraße 74
01307 Dresden
Ph.:
+49-351-458 3353
Fax:
+49-351-458 5716
E-mail:
[email protected]
Homepage: http://www.oncoray.de/index.php?id=39
Education:
1994-2000
2002
12/07
02/08
07/2013
Training:
2000-2001
2001-2006
student, TUD
Dr. med., Dept. of Radiation Oncology, TUD
Venia Legendi, TUD
Privatdozent, TUD
Professor for Translational Radiation Oncology
Postdoc, Radiobiological laboratory, Dept. of Radiation Oncology, University
Hospital Dresden, TUD
Residency, Dept. of Radiation Oncology, Universiy Hospital
Carl Gustav Carus Dresden
Clinical Experience:
2006
Consultant, Dept. of Radiation Oncology, University Hospital Carl Gustav
Carus Dresden, UKD
Since 2007
Responsible Medical Specialist (breast-, brain-, and gynaecological
carcinomas)
since 2013
responsible medical specialist for clinical and translational studies and for
brain tumours
Professional Appointments:
2007
Group leader „Radiobiology and experimental Radiotherapy of Tumors“,
Visiting Scientist, Princess Margaret Hospital, University of Toronto
2007 – 2009 Responsible Medical Specialist (breast-, brain- and, gynaecological
carcinomas)
Since 2009
Oberärztin, responsible of breast-, brain- and, gynaecological carcinomas
Since 2012
acting head, Dept. of radiation oncology, UKD
Since 2013
full professorship for Translational Radiation Research
Publications:
77 scientific publications in peer reviewed journals
Funding:
Extrabudgetary funding by DFG, DKH and Industry
Awards:
Carl Gustav Carus Förderpreis der TUD (2002), VARIAN – Juliana
Denekamp Award of the European Society for Therapeutic Radiation
Oncology (ESTRO) 2005; Hermann-Holthusen-Award of the DEGRO (2009)
Journals:
member of the Editorial Board and reviewer for Radiotherapy and Oncology
and Strahlentherapie Onkologie, Editor for British Journal of Radiology,
reviewer for several other journals
Societies:
Member of ESTRO-Clinical committee, member of DEGRO
Group members:
Scientists:
Research technicians:
Clinical trials unit:
Dr. rer. nat. Cläre von Neubeck, Dr. rer. nat. Ulrike Koch, Dr.
rer nat. Antje Dietrich, Dr. med. Annett Linge, Dr. med. Fabian
Lohaus, Dr. med. Annekatrin Seidlitz, Dr. rer nat. Armin Lühr,
Sebastian Zschaeck, Steffi Haberlau, Aline Jakob
Dorothee Pfitzmann, Katja Schumann, Liane Stolz-Kieslich,
Sigrid Balschukat, Elisabeth Jung
Monique Simon, Daniel Büttner, Carolin Haase, Evelin Klatt,
Ulrike Junker, Annett Klöber, Luisa Schünzel
Internal collaborators:
Wolfgang Enghardt, Leoni Kunz-Schughart, Nils Cordes, Jörg Pawelke, OncoRay
Jörg Steinbach, Jörg van den Hoff, Tom Cowan, Ulrich Schramm, Roland Sauerbrey,
Forschungszentrum Dresden Rossendorf und OncoRay
Jörg Kotzerke, Department of Nuclear Medicine
Michael Laniado, Institute of Diagnostic Radiology
Gustavo Baretton, Michael Muders, Institute of Pathology
Volker Gudziol, Head and neck surgery
Gabriele Schackert, Dietmar Krex, Neurosurgery
Manfred Wirth, Susanne Füssel, Dept. of Urology
External collaborators:
Daniel Zips, Hans-Peter Rodemann, Universität Tübingen
Jürgen Debus, Universität Heidelberg
Volker Budach, Inge Tinhofer, Charite´ Berlin
Claus Rödel, Universität Frankfurt
Anca Grosu, Ursula Nestle, Universität Freiburg
Stephanie Combs, TU München
Claus Belka, LMU München
Ekkehard Dikomey, Universität Hamburg
Howard D. Thames, Dept. of Biomathematics, MD Andersen Cancer Center Houston, USA
Robert G. Bristow, Princess Margaret Hospital Toronto, Canada
Jens Overgaard, Universität Aarhus, Dänemark
Gillies McKenna, Universität Oxford, UK
Participation in collaborative research projects (local, national, international):
BIOCARE – Molecular Imaging for Biologically Optimized Cancer Therapy (2004 - 2008),
European, FP 6
EMPIRION – European Masters Programme in Radiation Sciences in Oncology (2005 2008), European, FP 6
Tumorpathophysiologie (PSP-B.3 in Diagnose und Therapie maligner Erkrankungen) (2006 2008), BMBF
Radiobiologische und histologische Hypoxie humaner Plattenepithelkarzinome in
Nacktmäusen
und
deren
Relevanz
für
die
fraktionierte
Strahlentherapie
(Fortsetzungsantrag) (2006 - 2009), DFG
GENEPI-Entb2 - GENEtic pathways for the Prediction of the effects of irradiation –
European Normal and Tumor tissue Bank and database (2006 - 2009), EU (EURATOM)
GENEPI-lowRT (2006 - 2009), EU (EURATOM)
Wirkmechanismen und Ursachen der Heterogenität des Effektes von Inhibitoren des
epidermalen Wachstumsfaktorrezeptors (EGFR) in der Strahlentherapie solider Tumoren
(2007 - 2010), DFG
Onkologische Spitzenzentren (2007 - 2011), DKH
Functional assessment of DSB repair in human tumour samples. A novel tool to predict
therapeutic response (2009 - 2011), DKH
ULICE – Union of Light-Ion Centres in Europe (2009 - 2013), European FP 7
BMBF Centre for Innovation Competence (ZIK) OncoRay (2010-2015), national
BMBF Joint Research Project onCOOPtics – High Intensity Laser for Radiooncology (2007 2012), national
BMBF Kompetenzverbund Strahlenforschung (2008 – 2011), national
ALLEGRO – EArLy and Late hEalth risks to normal/healthy tissues from the use of existing
and emerGing techniques for RadiatiOntherapy (2009 - 2011), European FP 7
EORTC 40083
State Excellence Initiative Sachsen (2009-2013), SMWK, national/regional
Blockage of Neuropillin-2 for radiosensitization of prostate cancer (2011-2015), WilhelmSander Stiftung
BMBF German Cancer Consortium (DKTK) (2011-2015), national
List of 10 most important publications 2005-2014:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Lühr A, Löck S, Roth K, Helmbrecht S, Jakobi A, Petersen JP, Just U, Krause M,
Enghardt W, Baumann M (2014) Concept for Individualized Patient Allocation:
ReCompare - Remote Comparison of Particle and Photon Treatment Plans. Radiat
Oncol 9, 59
Koch U, Höhne K, von Neubeck C, Thames HD, Yaromina A, Dahm-Daphi J,
Baumann M*, Krause M* (*shared last authorship) (2013) Residual -H2AX foci
predict local tumour control after radiotherapy. Radiother Oncol 108, 434-39
Gurtner K, Deuse Y, Bütof R, Schaal K, Eicheler W, Oertel R, Grenman R, Thames
HD, Yaromina A, Baumann M, Krause M (2011) Diverse effects of combined
radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour
control and correlation with EGFR gene expression. Radiother Oncol 99, 323-30
Baumann M, Krause M (2010): CD44 - A Cancer Stem Cell-Related Biomarker with
Predictive Potential for Radiotherapy. Clinical Cancer Research 16, 5091-93, 2010
Baumann M, Krause M, Hill R (2008) Exploring the role of cancer stem cells in
radioresistance. Nat Rev Cancer 8(7): 545-54.
Krause M, Baumann M (2008). Clinical biomarkers of kinase activity: examples from
EGFR inhibition trials. Cancer Metast Rev, 27, 387-402.
Krause M, Prager J, Zhou X, Yaromina A, Dörfler A, Eicheler W, Baumann M (2007).
EGFR-inhibition before radiotherapy reduces tumour volume but does not improve
local control: differential response of cancer stem cells and nontumourigenic cells?
Radiother Oncol 83, 316-325
Krause M, Zips D, Thames HD, Kummermehr J, Baumann M (2006) Preclinical
evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother.
Oncol. 80: 112-122.
Krause M, Schütze C, Petersen C, Pimentel N, Hessel F, Harstrick A, Baumann M
(2005) Different classes of EGFR inhibitors may have different potential to improve
local tumor control after fractionated irradiation: A study on C225 in FaDu hSCC.
Radiother Oncol 74: 109-115.
Krause M, Ostermann G, Petersen C, Yaromina A, Hessel F, Harstrick A, van der
Kogel A, Thames HD, Baumann M (2005) Decreased repopulation as well as
increased reoxygenation contribute to the improvement in local control after targeting
of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76, 162-167